Qualigen Therapeutics Appoints New Chief Medical Officer
Ticker: AIXC · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1460702
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Qualigen Therapeutics names Dr. Paul E. M. Mann as CMO to boost drug development.
AI Summary
On October 3, 2024, Qualigen Therapeutics, Inc. announced the appointment of Dr. Paul E. M. Mann as Chief Medical Officer. Dr. Mann brings extensive experience in clinical development and medical affairs, previously holding leadership roles at various biopharmaceutical companies. This appointment is expected to bolster Qualigen's efforts in advancing its pipeline of novel therapeutics.
Why It Matters
The appointment of a new Chief Medical Officer signals a strategic move by Qualigen Therapeutics to strengthen its leadership team and drive forward its drug development programs.
Risk Assessment
Risk Level: low — The filing is a routine corporate announcement regarding an executive appointment and does not involve significant financial transactions or operational changes.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Dr. Paul E. M. Mann (person) — Appointed Chief Medical Officer
- October 3, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Paul E. M. Mann's appointment as Chief Medical Officer?
The filing reports October 3, 2024, as the date of the earliest event reported, which includes this appointment.
What is Qualigen Therapeutics, Inc.'s primary business?
Qualigen Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Qualigen Therapeutics, Inc. headquartered?
Qualigen Therapeutics, Inc. is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What was Qualigen Therapeutics, Inc. formerly known as?
The company was formerly known as RITTER PHARMACEUTICALS INC.
What is the filing date of this 8-K report?
This 8-K report was filed on October 9, 2024.
Filing Stats: 724 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-10-09 16:10:10
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex10-1.htm (EX-10.1) — 193KB
- 0001493152-24-040599.txt ( ) — 431KB
- qlgn-20241003.xsd (EX-101.SCH) — 3KB
- qlgn-20241003_lab.xml (EX-101.LAB) — 33KB
- qlgn-20241003_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: October 9, 2024 By: /s/ Kevin Richardson II Kevin Richardson II, Interim Chief Executive Officer